Resumen

BERMUDEZ A, F et al. Heparinas de Bajo Peso Molecular en la Cardiopatía Isquémica Metabólica. Bases Moleculares: Experiencia Clínica y Resultados. AVFT [online]. 2000, vol.19, n.2, pp.82-97. ISSN 0798-0264.

Low molecular weight heparin (LMHW) is isolated from unfractionated heparin (UFH). LMWH mechanism of action is exerted on Factor Xa through antithrombin. The most used LMWH are enoxaparin (Clexane), nadroparin (Fraxiparin) and deltaparin (Fragmin). A significant number of clinical assays have compared the effects of LMWH and UFH on deep venous thrombosis and pulmonary thromboembolism, showing LMWH better results than UFH. Based on these studies, dalteparin was used at a dose of 5000 IU/ day during 10 days; indobuphen 400 mg/day and trimetazidine 60 mg/day during 3 months in patients with ischemic cardiopathy. Our result show a significant improvement in these patients, through heart rate stabilization and absence of chest pain as well as tissue damage and necrosis in EKG. According to these results we suggest the use of this non invasive and ambulatory therapy in patients with ischemic cardiopathy.

Palabras clave : Low Molecular Weight heparin; Unfractionated heparin; Antithrombin; Ischemic-metabolic cardiopathy; Dalteparin.